AstraZeneca

Data presented from early breast cancer treatment trial

Published in Genetics and Environmental Health Week, January 5th, 2005

New data presented from the world's largest early breast cancer treatment trial (ATAC) report that ARIMIDEX reduced the relative risk of breast cancer recurrence by 17% over tamoxifen in the clinically relevant hormone receptor-positive patients for whom ARIMIDEX is indicated.

The presentation also reviewed the safety profile of ARIMIDEX compared to tamoxifen after 68 months of follow-up. ARIMIDEX and tamoxifen remain the only drugs approved by the FDA for the primary (treatment following surgery, with or without radiation) adjuvant treatment of hormone receptor-positive postmenopausal women with early breast cancer.

"It is crucial for women to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Genetics and Environmental Health Week

Source: Genetics and Environmental Health Week (2005-01-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry